Photo via CBS News

FDA says its abortion pill safety review will continue into next year

Read the original at CBS News ↗
Cite

FDA says its abortion pill safety review will continue into next year. (2026, October 8). CBS News. https://www.cbsnews.com/news/fda-abortion-pill-mifepristone-safety-review-2027-abortion-rights-opponents-angered/

Dated when The Aporia collected the article, usually within hours of publication. Check the original for its exact date and byline.

CBS News · collected 2026-10-08

Quick Summary

The Food and Drug Administration (FDA) announced that its review of mifepristone, commonly known as the abortion pill, will extend into next year. The FDA provided this update after being ordered by a federal judge in response to lawsuits from anti-abortion groups and states like Louisiana. Critics, such as Americans United for Life's Gavin Oxley, argue that this timeline reflects a lack of commitment to restricting the drug’s use. The FDA plans to complete a safety study by mid-December 2023 and issue a final report no later than March 2027 before deciding on any regulatory changes.
Written by AI on 2026-10-08, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

The FDA expects to complete its safety review of the abortion pill mifepristone by March 2027, according to a court filing made in response to a lawsuit brought by the state of Louisiana. The agency plans to compare mifepristone’s safety with surgical abortions up to 10 weeks gestation, analyzing data from approximately 100,000 women who have used the pill since its approval in 2000. Despite hundreds of peer-reviewed studies affirming its safety and effectiveness, recent political pressures under President Trump prompted a reevaluation of mifepristone's restrictions. The FDA temporarily lifted an in-person dispensation requirement for the drug but now may reconsider this decision based on new data gathered during the review process.

Written for “FDA Abortion Pill Review” on 2026-11-04, grounded in this article and the 2 other(s) covering the same event.

Story

📰 FDA Abortion Pill Review
Health · 3 article(s) covering the same event. Compare every outlet's account →

Compared with similar articles

This article reads unscored and hedges 15% of its claims. Each row says how that neighbour differs.
Toronto Star
Hedges 1 of 18 claims Outlet record 64/100
NBC News
⚖️ Leans left Hedges 4 of 20 claims Outlet record 78/100
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
20
sentences that state something as happening or true
Uncertain
15%
3 of 20 hedged ("reportedly", "may", "according to")
Leaning
withheld
no quote in the article backed the model's score
Publisher signals
65/100
CBS News's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
3
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-08 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

CBS News · 4566 article(s) · 7 correction(s) detected
Running correction rate · 7 correction(s)

Who wrote this

No reporter is named on this article.

Topics

FDA Health Louisiana The Food and Drug Administration Washington

Subjects

FDA ORG · 7× Louisiana GPE · 3× Trump PERSON · 2× Congress ORG · 1× Gavin Oxley PERSON · 1× Health ORG · 1× Robert F. Kennedy Jr. PERSON · 1× The Food and Drug Administration ORG · 1× Washington GPE · 1× the White House ORG · 1×

Narrative

The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr. was first approved by the FDA in 2000.
framing: assertive · carried by 1 article(s) · first seen 2026-10-08
🔮 The Food and Drug Administration says its of the nation's main pill will continue into next year, a timeline that was quickly condemned by abortion rights opponents hoping to see the drug's use curtailed.
2026-10-08 · CBS News
FDA says its abortion pill safety review will continue into next year · assertive framing

Claims (20 extracted, 3 hedged)

The Food and Drug Administration says its of the nation's main pill will continue into next year, a timeline that was quickly condemned by abortion rights opponents hoping to see the drug's use curtailed. asserted
use → say → opponents
The FDA gave a court-ordered update on its progress in a legal filing late Wednesday, providing the first substantive information about the controversial reevaluation ordered by Health Secretary Robert F. Kennedy Jr. was first approved by the FDA in 2000. asserted
FDA → give → 2000
The agency has repeatedly reaffirmed the pill's safety and effectiveness over the years, in addition to easing a number of restrictions on the drug, including dropping a requirement that it be dispensed in person. asserted
it → reaffirm → person
But since President Trump returned to the White House, anti-abortion rights groups and their allies in Congress have pushed the administration to revisit the pill, in the hopes of restricting its use. asserted
groups → return → use
The FDA said in its filing that it expects to complete a safety study of the pill by mid-December this year. asserted
it → say → -
A report on the findings is expected "no later than March 2027," after which the agency will decide whether to impose new restrictions or other changes on the drug's use. asserted
agency → expect → use
Gavin Oxley, of Americans United for Life, an anti-abortion group, criticized the move as a lack of "true leadership" by Trump administration officials. asserted
Oxley → criticize → officials
"The administration continues to find itself on the wrong side of women's health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill," Oxley said. asserted
Oxley → continue → pill
The two-drug regimen of mifepristone, combined with a second drug, misoprostol, is the most common form of abortion in the U.S. asserted
regimen → combine → U.S.
The FDA was directed to provide the latest update by a federal judge in a case brought by the state of Louisiana alleging that mail delivery of mifepristone . asserted
FDA → direct → mifepristone
It's one of several state lawsuits related to mifepristone winding their way through the courts. asserted
It → relate → courts
Last month, a three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana's case, including whether the state had the legal standing to challenge the FDA's oversight of mifepristone. asserted
state → question → mifepristone
Any ruling from the 5th Circuit on the Louisiana case wouldn't immediately change the landscape because the Supreme Court has blocked changes to the drug until it sees the case again. asserted
it → change → case
The FDA said Wednesday it is using a "statistical data mining method" to discover "unknown safety concerns" that may exist with the drug. uncertain
that → say → drug
The data comes from an electronic database that collects reports of medical injuries and drug side effects from major health networks and insurers. asserted
that → come → networks
In addition to the safety study, the agency said it is considering a number of petitions proposing changes to how mifepristone is prescribed and distributed. asserted
mifepristone → say → changes
Abortion opponents have focused most of their efforts on a 2021 decision allowing doctors to prescribe the drug online and send it through the mail during COVID-19. asserted
doctors → focus → COVID-19
That decision, made permanent under President Joe Biden in 2023, had the effect of undermining a number of state abortion bans, since women can receive the drug through the mail. asserted
women → make → mail
Asked in 2025 whether a review of mifepristone could lead to a ban, CBS News medical correspondent Dr. Celine Gounder suggested it would be difficult for the FDA to withdraw approval, an extraordinary step that would quickly draw legal challenges. uncertain
that → ask → challenges
However, Gounder said that depending on what the safety review finds, it could make access more difficult, limiting the drug's availability through telehealth or by mail, or restricting the ability to prescribe it to doctors rather than physician assistants or nurses who are also currently able to prescribe it. uncertain
who → say → it
💬Give feedback
🕘History 🎫Support